Defendant: Sun Pharmaceutical / Taro and Sandoz | Category: Antitrust & Price-Fixing | Added: 2026-07-12
Alleged Issue
The litigation alleges generic-drug manufacturers engaged in anticompetitive conduct that inflated the prices of certain generic prescription drugs paid by end payers.
Eligibility
U.S. consumers and third-party payers who purchased or paid for the generic prescription drugs covered by the Sun/Taro and Sandoz settlement classes during the applicable class periods (broadly, generic-drug purchases from May 1, 2009 through December 31, 2019).
Estimated Payout
varies (pro rata cash based on covered generic-drug spend and number of valid claims)
Claim Deadline
None
Background
The official notice site is maintained by the notice administrator for In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-MD-2724, in the U.S. District Court for the Eastern District of Pennsylvania. It covers multiple settlements, including a Sun/Taro class and a Sandoz class that are open to both consumers and third-party payers, plus Apotex and Heritage classes limited to third-party payers. End payers must submit a claim form online or by mail, and the notice stresses that class members do not need to hire or pay a claims-recovery firm to participate. Claims must be submitted or postmarked by November 9, 2026.